MedTrace Logo

User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes

NCT07052292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2026-04-09

No results posted yet for this study

Summary

This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DEVICE

DuraTouch®

Participants will subcutaneously inject the insulin using DuraTouch®.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-01-09
Completion
2026-01-09
FDA Device
Yes

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052292 on ClinicalTrials.gov